CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 208 enrolled
Drug / intervention
Belantamab mafodotin +8 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04126200
NCT04126200Phase 2Active
CompareCT.gov

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5

GlaxoSmithKline·interventional·Posted Oct 15, 2019·Updated May 6, 2026

In Brief

A Phase 2 clinical trial evaluating Belantamab mafodotin, GSK3174998, and 7 other interventions for Multiple Myeloma. Active but no longer recruiting, targeting 208 participants across 38 sites in 13 countries.

Detailed Summary

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phase I/II, randomized, open-label, platform study designed to evaluate the effects of belantamab mafodotin in combination with other anti-cancer drugs in participants with relapsed/refractory multiple myeloma. The Platform design incorporates a single master protocol, where multiple treatment combinations, as sub-studies, will be evaluated simultaneously.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesBrazil, Canada, France, Germany, Greece, Mexico, Netherlands, Norway, Poland, South Korea, Spain, Sweden, United States
Collaborators--

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedOct 15, 2019
Enrollment StartOct 7, 2019
Primary CompletionApr 17, 2025
Study CompletionMar 11, 2027
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 6.7 years ago

Interventions

Belantamab mafodotindrug

Belantamab mafodotin will be administered.

GSK3174998drug

GSK3174998 will be administered.

Feladilimabdrug

feladilimab will be administered.

Nirogacestatdrug

Nirogacestat will be administered.

Dostarlimabdrug

Dostarlimab will be administered.

Isatuximabdrug

Isatuximab will be administered.

Lenalidomidedrug

Lenalidomide will be administered.

Dexamethasonedrug

Dexamethasone will be administered.

Pomalidomidedrug

Pomalidomide will be administered.